Esperion settles patent dispute with Alkem over cholesterol drugs

Esperion Therapeutics, a pharmaceutical company specializing in cholesterol treatments, announced a settlement of its patent dispute with Indian pharmaceutical firm Alkem Laboratories regarding their competing cholesterol-lowering drugs in New York on October 15, 2023, after months of legal battles over intellectual property rights in the lucrative cardiovascular drug market. The resolution ends a complex legal battle that began in early 2023 when Esperion accused Alkem of infringing on patents related to its innovative bempedoic acid-based cholesterol treatment, with the dispute centered on whether Alkem's generic version violated Esperion's intellectual property rights. Both companies expressed satisfaction with the agreement, which includes undisclosed financial terms that industry analysts estimate could be worth tens of millions of dollars, and noted that it allows them to focus on their respective research and development initiatives without the burden of ongoing litigation. The settlement comes at a critical time for both companies as they navigate an increasingly competitive pharmaceutical landscape, with the cholesterol drug market valued at over $20 billion globally, and may set a precedent for future patent disputes in the cardiovascular medication sector.